Nuti M, Mottolese M, Viora M, Donnorso R P, Schlom J, Natali P G
Int J Cancer. 1986 Apr 15;37(4):493-8. doi: 10.1002/ijc.2910370404.
Fine-needle aspiration cytology (FNAC) is currently used in evaluating the nature of breast nodules. In the present study we have examined whether monoclonal antibodies (MAbs) to breast-tumor-associated antigens (BTAA) can be employed in FNAC for the diagnosis of breast cancer. For this purpose we have used 2 murine MAbs recognizing 2 distinct BTAA expressed by breast tumors, irrespective of their histotype, in an indirect avidin-biotin immunohistochemical technique on aspirate smears. The results of this study show that, while benign lesions are consistently negative, tumor cells containing aspirates are reactive with at least one MAb in 95% of the cases. Thus, selected MAbs to BTAA may be a powerful diagnostic tool in conjunction with conventional cytology, and because of the objective interpretation of the immunohistochemical findings, FNAC of the breast can eventually be extended outside specialized institutions.
细针穿刺细胞学检查（FNAC）目前用于评估乳腺结节的性质。在本研究中，我们检验了针对乳腺肿瘤相关抗原（BTAA）的单克隆抗体（MAb）是否可用于FNAC诊断乳腺癌。为此，我们使用了2种鼠源MAb，它们可识别乳腺肿瘤表达的2种不同的BTAA，无论其组织类型如何，采用间接抗生物素蛋白-生物素免疫组织化学技术对穿刺涂片进行检测。本研究结果表明，良性病变始终为阴性，而在95%的病例中，含有抽吸物的肿瘤细胞与至少一种MAb发生反应。因此，选择的针对BTAA的MAb可能是一种与传统细胞学相结合的强大诊断工具，并且由于免疫组织化学结果的客观解释，乳腺FNAC最终可推广至专业机构以外的地方。
